Analysis and Purification of Antibody Fragments Using Protein A, Protein G, and Protein L

Griep, R.A.; McDougall, John G.

doi:10.1007/978-3-642-01147-4_24

Cited by 3 publications

(1 citation statement)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Purification by Protein A, Protein G and Protein L of Fab fragments of different isotypes are standard methods used to isolate Fabs. Ion exchange and size exclusion chromatography are also used [16,17].…”

Section: Antibody Fab Fragmentsmentioning

confidence: 99%

Antibody fragments: Prolonging circulation half-life special issue-antibody research

Herrington-Symes¹,

Farys²,

Khalili³

et al. 2013

ABB

View full text Add to dashboard Cite

Antibodies are currently the fastest growing class of therapeutic proteins. When antibody fragments are included, there are over thirty-five antibody-based medicines approved for human therapy. Many more antibody and antibody-like fragments are being evaluated clinically. Production of antibody fragments can be efficient and their compact size can allows for better tissue extravasation into solid tumors than full antibodies. Unfortunately, a key limitation of antibody fragments for systemic use is their short half-life in circulation. Prolonging their circulation half-life can be accomplished clinically by the covalent conjugation of the antibody fragment to the water-soluble polymer, poly(ethylene glycol) (PEG). Many polymers and strategies are also being pursued to increase antibody fragment half-life.

show abstract

Section: Antibody Fab Fragmentsmentioning

confidence: 99%

Antibody fragments: Prolonging circulation half-life special issue-antibody research

Herrington-Symes¹,

Farys²,

Khalili³

et al. 2013

ABB

View full text Add to dashboard Cite

show abstract

A simple scheme for large scale purification of urine – Derived Bence Jones Kappa protein

Badgujar¹,

Rane²,

Palav³

et al. 2022

Journal of Chromatography B

View full text Add to dashboard Cite

Protein L—More Than Just an Affinity Ligand

et al. 2021

View full text Add to dashboard Cite

In the past 30 years, highly specific drugs, known as antibodies, have conquered the biopharmaceutical market. In addition to monoclonal antibodies (mAbs), antibody fragments are successfully applied. However, recombinant production faces challenges. Process analytical tools for monitoring and controlling production processes are scarce and time-intensive. In the downstream process (DSP), affinity ligands are established as the primary and most important step, while the application of other methods is challenging. The use of these affinity ligands as monitoring tools would enable a platform technology to monitor process steps in the USP and DSP. In this review, we highlight the current applications of affinity ligands (proteins A, G, and L) and discuss further applications as process analytical tools.

show abstract

Analysis and Purification of Antibody Fragments Using Protein A, Protein G, and Protein L

Cited by 3 publications

References 41 publications

Antibody fragments: Prolonging circulation half-life special issue-antibody research

Antibody fragments: Prolonging circulation half-life special issue-antibody research

A simple scheme for large scale purification of urine – Derived Bence Jones Kappa protein

Protein L—More Than Just an Affinity Ligand

Contact Info

Product

Resources

About